Last update: Dec. 1, 2004

Levosimendan

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

No untoward effect has been described, but blood hypotension and cardiac arrhytmias are likely.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Levosimendan belongs to this group or family:

Tradenames

Main tradenames from several countries containing Levosimendan in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 280 daltons
Protein Binding 97 %
Tmax 48 hours
T1/2 80 hours

References

  1. Kearney L, Wright P, Fhadil S, Thomas M. Postpartum Cardiomyopathy and Considerations for Breastfeeding. Card Fail Rev. 2018 Abstract Full text (link to original source) Full text (in our servers)

Total visits

2,007

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM